Investigation of AZD5492 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults with Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies

The primary objective of this study is to evaluate the **safety** and **tolerability** of AZD5492 in adult participants diagnosed with **Systemic Lupus Erythematosus** or **Idiopathic Inflammatory Myopathies**. Assessing the safety profile is clinically relevant as it determines the potential risks associated with the administration of AZD5492, which is crucial for ensuring patient safety and guiding future therapeutic use. Additionally, the study aims to investigate the **pharmacokinetics** and **pharmacodynamics** of AZD5492, providing insights into the drug's absorption, distribution, metabolism, and excretion, as well as its biological effects and mechanism of action in the target population.

The clinical trial involves a total of **30 participants** diagnosed with **Systemic Lupus Erythematosus** and **Idiopathic Inflammatory Myopathies**. The study population includes both male and female subjects, with an age range that spans from adolescents to adults. Participants were selected to include a vulnerable population, although specific selection criteria are not provided. The trial does not specify any particular lifestyle considerations such as diet or physical activity. The sponsor has not disclosed detailed inclusion or exclusion criteria for this study.

The clinical trial is designed to evaluate the **safety**, tolerability, pharmacokinetics, and pharmacodynamics of AZD5492 in adult participants diagnosed with **Systemic Lupus Erythematosus** or **Idiopathic Inflammatory Myopathies**. This study is structured as a Phase 1 trial, employing a randomized, double-blind, and controlled methodology to ensure the reliability and validity of the results. The trial is expected to commence recruitment on April 30, 2025, and is projected to conclude by February 17, 2028, encompassing a comprehensive duration to adequately assess the investigational product's effects.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This initial visit will involve a thorough assessment of the participant's medical history and current health status. Following successful screening, participants will be randomized into treatment groups and will attend regular follow-up visits. These visits are designed to monitor the participants' health, assess the investigational product's effects, and ensure adherence to the study protocol. The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to gather comprehensive data on the investigational product's impact.

The expected length of participant involvement will vary depending on individual response and adherence to the study protocol. However, participants are anticipated to be involved for the duration of the trial unless specific conditions necessitate early termination. Such conditions may include adverse reactions, non-compliance with study procedures, or withdrawal of consent. The trial's design and procedures are meticulously crafted to uphold the highest standards of scientific rigor and participant safety, ensuring that the data collected will contribute valuable insights into the treatment of these complex medical conditions.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is April 30, 2025, with an anticipated end date of February 17, 2028. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy alongside safety evaluations. These assessments may include the use of validated scales, laboratory tests, or patient-reported outcomes to gather data on the investigational product's effects. The schedule for measuring and collecting efficacy data is not specified, but it is common for such trials to include multiple timepoints throughout the study duration to monitor changes and trends. The analysis of collected data will likely involve statistical methods appropriate for early-phase trials, focusing on identifying any initial signs of efficacy that warrant further investigation in subsequent trial phases.